Cereno Scientific announced that Dr. Raymond L. Benza, M.D., FACC, FAHA, FACP, USA, has joined the company's Scientific Advisory Board (SAB). Dr. Benza is a global thought leader within pulmonary arterial hypertension (PAH) and has been working as an advisor to the company's Phase II program with drug candidate CS1 in PAH.